Document is current
Any future updates will be listed below
-
Authors
Ughetto, Stefano
Migliore, Cristina
Pietrantonio, Filippo
Apicella, Maria
Petrelli, Annalisa
D’Errico, Laura
Durando, Stefania
Moya-Rull, Daniel
Bellomo, Sara E.
Rizzolio, Sabrina
Capelôa, Tania
Ribisi, Salvatore
Degiuli, Maurizio
Reddavid, Rossella
Rapa, Ida
Fumagalli, Uberto
De Pascale, Stefano
Ribero, Dario
Baronchelli, Carla
Sgroi, Giovanni
Rausa, Emanuele
Baiocchi, Gian Luca
Molfino, Sarah
Manenti, Stefania
Bencivenga, Maria
Sacco, Michele
Castelli, Claudia
Siena, Salvatore https://orcid.org/0000-0002-2681-2846
Sartore-Bianchi, Andrea
Tosi, Federica
Morano, Federica
Raimondi, Alessandra
Prisciandaro, Michele
Gloghini, Annunziata
Marsoni, Silvia
Sottile, Antonino
Sarotto, Ivana
Sapino, Anna
Marchiò, Caterina
Cassoni, Paola
Guarrera, Simonetta
Corso, Simona
Giordano, Silvia https://orcid.org/0000-0003-1854-1086
-
Funding
Funding for this research was provided by:
Associazione Italiana per la Ricerca sul Cancro (IG 20210, IG 21770, IG 23624, IG 22850)
Ministero dell’Istruzione, dell’Università e della Ricerca (PRIN 2015)
Fondazione Piemontese per la Ricerca sul Cancro (5X1000 Min. Salute 2013, 5X1000 2014 Min. Salute, 5X1000 2014 Min. Salute, 5X1000 2015 Min. Salute, 5X1000 2015 Min. Salute, 5X1000 2015 Min. Salute “Strategy”)
Ministero della Salute (Ricerca Corrente 2019)
- License Information
-
More Information
Article History
Received: 2 October 2020
Accepted: 28 January 2021
First Online: 23 March 2021
Compliance with ethical standards
:
: FP received honoraria from Amgen, Roche, Lilly, Bayer, Servier, Merck-Serono, Sanofi. Research grants from BMS; AS-B. participated in advisory boards for Amgen, Bayer, Samsung Bioepis and Sanofi. S. S is advisory board member for Amgen, Bayer, BMS, CheckmAb, Clovis, Daiichi-Sankyo, Merck, Roche-Genentech, and Seattle Genetics. CM has received personal/consultancy fees from Axiom Healthcare Strategies, Daiichi-Sankyo, MSD, Roche and Bayer.The remaining authors declare no potential conflicts of interest.
Free to read: This content has been made available to all.
